Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea

NCT01462370 is registered in ClinicalTrials.gov with Organon and Co as lead sponsor.

NCT NCT01462370
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462370 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Active-Comparator-Controlled, 2-period, Crossover, Double-Blind Study in China to Assess the Safety and Efficacy of Etoricoxib 120 mg Versus Ibuprofen up to 2400 mg (600 mg Q6h) in the Treatment of Patients With Primary Dysmenorrhea
Lead sponsor
Organon and Co
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
June 30, 2012
Enrollment
139 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

dysmenorrhea